KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Repurchased
Ratios

Resmed (RMD) EBIAT (2016 - 2025)

Historic EBIAT for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $392.6 million.

  • Resmed's EBIAT rose 1391.99% to $392.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year increase of 1899.33%. This contributed to the annual value of $1.4 billion for FY2025, which is 3719.79% up from last year.
  • Latest data reveals that Resmed reported EBIAT of $392.6 million as of Q4 2025, which was up 1391.99% from $348.5 million recorded in Q3 2025.
  • In the past 5 years, Resmed's EBIAT ranged from a high of $392.6 million in Q4 2025 and a low of -$78.5 million during Q1 2021
  • For the 5-year period, Resmed's EBIAT averaged around $247.8 million, with its median value being $227.3 million (2022).
  • Its EBIAT has fluctuated over the past 5 years, first tumbled by 14810.74% in 2021, then surged by 32809.6% in 2022.
  • Resmed's EBIAT (Quarter) stood at $201.8 million in 2021, then rose by 11.48% to $224.9 million in 2022, then fell by 7.16% to $208.8 million in 2023, then skyrocketed by 65.05% to $344.6 million in 2024, then grew by 13.92% to $392.6 million in 2025.
  • Its EBIAT was $392.6 million in Q4 2025, compared to $348.5 million in Q3 2025 and $379.7 million in Q2 2025.